– Royal Brisbane and Women’s Hospital acquisition is intended to expand access to potentially life-saving radiotherapy treatments to more patients
– Hospital was the first in Australia to invest in the TomoTherapy(R) helical radiotherapy delivery platform and is now the first to secure the latest generation Radixact(R) System
Accuray Incorporated (NASDAQ: ARAY) announced today that Royal Brisbane and Women’s Hospital (RBWH), the largest medical facility in Queensland, Australia, has selected two Radixact ( https://c212.net/c/link/?t=0&l=en&o=3442453-1&h=3923730603&u=https%3A%2F%2Fwww.accuray.com%2Fradixact%2F&a=Radixact ) Systems with ClearRT(TM) ( https://c212.net/c/link/?t=0&l=en&o=3442453-1&h=103494317&u=https%3A%2F%2Fwww.accuray.com%2Fclearrt%2F&a=ClearRT ) helical fan-beam kVCT imaging and Synchrony(R) ( https://c212.net/c/link/?t=0&l=en&o=3442453-1&h=33759400&u=https%3A%2F%2Fwww.accuray.com%2Fsoftware%2Fsynchrony%2F&a=Synchrony ) artificial intelligence (AI)-driven four-dimensional (4D) dynamic delivery technology to expand access to potentially life-saving radiotherapy treatments to more patients. The Radixact Systems will replace existing, older TomoTherapy(R) Systems and in combination with ClearRT and Synchrony, are designed to provide unprecedented versatility in the types of tumors and indications that can be treated – and superior efficiency, precision and accuracy in radiation treatment delivery.
High-quality images are crucial to each step of the radiotherapy treatment workflow. ClearRT, a helical CT imaging solution, was created to empower medical care teams to produce exceptional diagnostic-like quality CT images, quickly and cost-effectively. ClearRT imaging enables high confidence in the patient set-up and registration that form the basis of radiation therapy treatment planning, delivery and monitoring, and are key to the successful treatment of organ-confined, locally advanced and metastatic tumors. ClearRT also integrates with other Accuray-only applications, such as Synchrony, a sophisticated technology that adapts treatment delivery to tumor motion in real time.
“We value our long-standing partnership with the RBWH team and are honored they made the decision to upgrade to the Radixact System integrated with ClearRT and Synchrony – novel solutions that we believe will enable them to advance patients’ quality of care,” said Suzanne Winter, president at Accuray. “The Radixact System is a workhorse radiotherapy device capable of efficiently and effectively treating the routine cases seen daily, as well as the most difficult cases when needed. We are committed to supporting our customers with innovative new products that improve the lives of people diagnosed with cancer and facilitate its management as a long-term, chronic condition.”
RBWH is a world-leading healthcare, research and innovation hub, known for its preeminent cancer care. In 2019, RBWH’s multidisciplinary staff provided more than 153,023 cancer care treatments, consultations, and admissions. alphaXRT, as the exclusive distributor, installer and training partner for the Accuray CyberKnife(R) and TomoTherapy(R) platform portfolios in Australia and New Zealand, worked with the RBWH team as they evaluated radiotherapy systems and selected the Radixact(R) System with ClearRT(TM) and Synchrony(R).
RBWH is seeing an increasing number of patients diagnosed with cancer. When the hospital’s medical care team decided to upgrade their TomoTherapy Systems, they felt it was important to select a fast, versatile device capable of precisely treating virtually any indication and complexity. Based on the team’s experience with TomoTherapy, they considered Radixact to be the ideal system for them. It offers continuous 360-degree precision plus much needed flexibility with the integration of ClearRT and Synchrony. Once installed, they will have access to a powerful set of tools for increasing patient throughput while delivering (ultra) hypofractionated and conventionally fractionated treatments, personalized to the unique requirements of each patient.
Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook ( https://c212.net/c/link/?t=0&l=en&o=3442453-1&h=3310436001&u=https%3A%2F%2Fwww.facebook.com%2FAccurayIncorporated%2F&a=Facebook ), LinkedIn ( https://c212.net/c/link/?t=0&l=en&o=3442453-1&h=3381291289&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Faccuray%2Fmycompany%2F&a=LinkedIn ), Twitter ( https://c212.net/c/link/?t=0&l=en&o=3442453-1&h=2235083213&u=https%3A%2F%2Ftwitter.com%2Faccuray&a=Twitter ), and YouTube ( https://c212.net/c/link/?t=0&l=en&o=3442453-1&h=1728190709&u=https%3A%2F%2Fwww.youtube.com%2Fuser%2FAccurayIncorporated&a=YouTube ).
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient experiences and patient outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company’s assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company’s ability to achieve widespread market acceptance of its products, including new product innovations and releases; the company’s ability to develop new products or improve existing products to meet customers’ needs; the company’s ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands and such other risks identified under the heading “Risk Factors” in the company’s quarterly report on Form 10-Q, filed with the Securities and Exchange Commission (the “SEC”) on January 28, 2022, and as updated periodically with the company’s other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Beth Kaplan Christy Maginn
+1 (408) 789-4426 +1 (703) 297-7194
SOURCE Accuray Incorporated